GRCL Stock Overview Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Gracell Biotechnologies Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Gracell Biotechnologies Historical stock prices Current Share Price US$10.25 52 Week High US$10.44 52 Week Low US$1.40 Beta -0.35 1 Month Change 2.30% 3 Month Change 93.40% 1 Year Change 388.10% 3 Year Change -57.85% 5 Year Change n/a Change since IPO -59.10%
Recent News & Updates
Gracell Biotechnologies Files Form 15 Mar 05
AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders. Feb 24 Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Composite Index AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders.
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR) Feb 21
Price target decreased by 9.7% to US$10.58 Dec 27 See more updates
Gracell Biotechnologies Files Form 15 Mar 05
AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders. Feb 24 Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Composite Index AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders.
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR) Feb 21
Price target decreased by 9.7% to US$10.58 Dec 27
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus Dec 22
Gracell Biotechnologies Inc. Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma At ASH 2023 Dec 19
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023 Dec 12
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus Nov 29
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus Nov 28
Founder notifies of intention to sell stock Nov 24
New major risk - Revenue and earnings growth Nov 12
Price target decreased by 11% to US$11.43 Nov 10
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65h American Society of Hematology Annual Meeting & Exposition Nov 04
Gracell Biotechnologies Inc. to Present Data Highlighting Preclinical Efficacy of Smart Cart Against Solid Tumors At Society for Immunotherapy of Cancer 38th Annual Meeting Nov 01
Gracell Biotechnologies Inc. to Report Q3, 2023 Results on Nov 13, 2023 Oct 31
Gracell Biotechnologies Reports Updated Clinical Data for Fastcar-T Gc012f for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate Sep 28
Gracell Biotechnologies Doses First Patient in Phase 1B/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma Sep 27
Founder notifies of intention to sell stock Aug 25
New minor risk - Shareholder dilution Aug 13 Gracell Biotechnologies Inc. announced that it expects to receive $150.008003 million in funding from a group of investors Aug 09
Gracell Biotechnologies Inc. announced that it expects to receive $150.008003 million in funding from a group of investors Aug 08
Gracell Biotechnologies Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 01
Founder notifies of intention to sell stock Jun 19
Gracell Biotechnologies Inc. Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate Jun 12
Gracell Biotechnologies Inc., Annual General Meeting, Jul 13, 2023 Jun 06
Gracell Biotechnologies Inc. Initiates Investigational Study Evaluating Gc012f for Treatment of Refractory Systemic Lupus Erythematosus May 19
Founder notifies of intention to sell stock Apr 17
Price target decreased by 12% to US$12.57 Mar 15
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma Feb 14
Gracell Biotechnologies Inc. Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma Feb 04
Gracell Biotechnologies Inc. Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate Dec 11
Founder notifies of intention to sell stock Dec 09
Less than half of directors are independent Nov 16
Founder notifies of intention to sell stock Nov 16
Gracell Biotechnologies Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 01
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-Cell Acute Lymphoblastic Leukemia Oct 18
Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform Sep 22
Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02 Aug 15
Gracell Biotechnologies Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 03 Gracell Biotechnologies Inc. Appoints Dr. Wendy Li as Chief Medical Officer
Gracell Biotechnologies rallies after naming new chief medical officer Aug 01
Gracell Biotechnologies Inc. Appoints Veteran Biopharma Executive Dr. Samuel Zhang as Chief Business Officer Jul 20
Gracell names Dr. Samuel Zhang as Chief Business Officer Jul 19
Chief Medical Officer notifies of intention to sell stock Jun 20
Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-Targeting FasTCAR GC012F in RRMM at EHA2022 Congress Jun 13
Gracell Biotechnologies Inc. to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting Car-T GC012f for Relapsed/Refractory Multiple Myeloma At 2022 ASCO Annual Meeting Jun 01
Price target decreased to US$19.00 May 30
Gracell Biotechnologies Inc. to Report Q1, 2022 Results on May 16, 2022 May 03
Less than half of directors are independent Apr 27
Gracell Biotechnologies Inc. Announces Early Results of First-In-Human Clinical Study of GC502 for Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Apr 09
Price target decreased to US$28.33 Mar 15
Gracell Biotechnologies Inc. to Report Q4, 2021 Results on Mar 14, 2022 Mar 04
Gracell Biotechnologies Inc. Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform Feb 24
Gracell Biotechnologies Inc. Doses First Patients in First-In-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma Feb 18
Chief Medical Officer notifies of intention to sell stock Dec 12
Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment Nov 26
Forecast to breakeven in 2025 May 21
Gracell Biotechnologies Inc. to Present Updated Results of Gc012f Fastcar-Enabled Bcma/Cd19 Dual-Targeting Car-T Cell Therapy for Relapsed/Refractory Multiple Myeloma At Asco 2021 and Eha 2021 May 21
Gracell Biotechnologies Inc. to Report Q4, 2020 Results on Mar 09, 2021 Feb 24
Gracell ends IPO quiet period with favorable views from analysts Feb 02
Gracell Biotechnologies Inc. Receives IND Approval from China NMPA for GC019F Jan 20
Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products Jan 16
China NMPA Grants Approval to Gracell Biotechnologies Inc. for Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for Treatment of Relapsed or Refractory B-ALL Jan 14
Gracell Biotechnologies Inc. has completed an IPO in the amount of $209 million. Jan 09 Shareholder Returns GRCL US Biotechs US Market 7D -0.2% -0.2% 3.2% 1Y 388.1% -6.9% 24.0%
See full shareholder returns
Return vs Market: GRCL exceeded the US Market which returned 22.3% over the past year.
Price Volatility Is GRCL's price volatile compared to industry and market? GRCL volatility GRCL Average Weekly Movement 19.0% Biotechs Industry Average Movement 11.1% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.2%
Stable Share Price: GRCL's share price has been volatile over the past 3 months.
Volatility Over Time: GRCL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company’s product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies.
Show more Gracell Biotechnologies Inc. Fundamentals Summary How do Gracell Biotechnologies's earnings and revenue compare to its market cap? GRCL fundamental statistics Market cap US$990.82m Earnings (TTM ) -US$69.13m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GRCL income statement (TTM ) Revenue CN¥0 Cost of Revenue CN¥0 Gross Profit CN¥0 Other Expenses CN¥496.98m Earnings -CN¥496.98m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/02/21 07:31 End of Day Share Price 2024/02/21 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Gracell Biotechnologies Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Justin Zelin BTIG Louise Chen Cantor Fitzgerald & Co. Yigal Nochomovitz Citigroup Inc
Show 5 more analysts 
